SCHEMBL4883748

SCHEMBL4883748

CC(=O)SCC(=O)c1ccc(OCCNc2cnc3ccccc3c2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 15/20 0.48
HDAC3 O15379 14/20 0.48
HDAC4 P56524 14/20 0.48
HDAC1 Q13547 14/20 0.48
HDAC7 Q8WUI4 14/20 0.48
HDAC2 Q92769 14/20 0.48
HDAC10 Q969S8 14/20 0.48
HDAC11 Q96DB2 14/20 0.48
HDAC8 Q9BY41 14/20 0.48
HDAC9 Q9UKV0 14/20 0.48
HDAC5 Q9UQL6 14/20 0.48
RAB9A P51151 2/20 0.43
KDM4E B2RXH2 1/20 0.43
NPC1 O15118 1/20 0.43
MITF O75030 1/20 0.43
XBP1 P17861 1/20 0.43
PAX8 Q06710 1/20 0.43
KLF5 Q13887 1/20 0.43
TRPV1 Q8NER1 2/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL845888 0.71 TRPV1 (0.76) RAB9AKDM4ENPC1MITFXBP1
SCHEMBL4885207 0.71 HDAC3 (0.56) HDAC6HDAC3HDAC4HDAC1HDAC7
SCHEMBL4887086 0.69 TSHR (0.53) HDAC6HDAC3HDAC4HDAC1HDAC7
SCHEMBL29432990 0.69 KDR (0.55) HDAC6HDAC3HDAC4HDAC1HDAC7
SCHEMBL846555 0.69 RAB9A (0.71) RAB9AKDM4ENPC1MITFXBP1
SCHEMBL27679373 0.68 HDAC6 (0.58) HDAC6HDAC3HDAC4HDAC1HDAC7
SCHEMBL5432536 0.67 HDAC3 (0.73) HDAC6HDAC3HDAC4HDAC1HDAC7
SCHEMBL5796726 0.67 RAB9A (0.56) HDAC6RAB9AKDM4ENPC1TRPV1
SCHEMBL19616555 0.66 HDAC6 (0.72) HDAC6RAB9AKDM4ENPC1MITF
SCHEMBL447481 0.66 NPC1 (0.54) HDAC6HDAC3HDAC4HDAC1HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080194681-A1 Novel Inhibitors of Histone Deacetylase for the Treatment of Disease KALYPSYS, INC. (US) 2008-08-14 US disclosed
US-20080194681-A1 Novel Inhibitors of Histone Deacetylase for the Treatment of Disease KALYPSYS, INC. (US) 2008-08-14 US disclosed
US-20080194681-A1 Novel Inhibitors of Histone Deacetylase for the Treatment of Disease KALYPSYS, INC. (US) 2008-08-14 US disclosed
EP-1819669-A2 NOVEL INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE Kalypsys, Inc. (US) 2007-08-22 EP disclosed
WO-2006063294-A2 NOVEL INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194681-A1 Novel Inhibitors of Histone Deacetylase for the Treatment of Disease HDAC1, HDAC10, HDAC6 HDAC6 3/4885HDAC3 11/4885HDAC4 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.